To confirm the binding specificity of the IGF2BP3 antibody, and validate the prognostic value of IGF2BP3 in future studies, we performed Western blotting of a human liposarcoma cell line, LPS2, following CRISPR-cas9 mediated IGF2BP3 knockdown [19,43]. This evidence concerns the gene IGF2BP3 and liposarcoma.